.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
CLEAR Outcomes tested bempedoic acid in patients who were unable or unwilling to take guideline-recommended statin doses. Over a median follow-up of about 41 months, bempedoic acid lowered LDL cholesterol and reduced the risk of major cardiovascular events compared with placebo. The study is clinically useful because statin intolerance is a frequent reason for undertreatment of dyslipidemia. Bempedoic acid acts upstream of cholesterol synthesis in the liver and is activated predominantly in hepatic tissue, which may limit muscle-related adverse effects. For internists, the trial supports an evidence-based non-statin option when LDL cholesterol remains above target despite maximally tolerated therapy. Patient assessment should distinguish true statin-associated symptoms from nocebo effects, drug interactions or unrelated musculoskeletal conditions, because statins remain foundational therapy. When additional treatment is needed, selection should reflect absolute ASCVD risk, expected LDL reduction, cost, route of administration and patient preference.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
CLEAR Outcomes tested bempedoic acid in patients who were unable or unwilling to take guideline-recommended statin doses. Over a median follow-up of about 41 months, bempedoic acid lowered LDL cholesterol and reduced the risk of major cardiovascular events compared with placebo. The study is clinically useful because statin intolerance is a frequent reason for undertreatment of dyslipidemia. Bempedoic acid acts upstream of cholesterol synthesis in the liver and is activated predominantly in hepatic tissue, which may limit muscle-related adverse effects. For internists, the trial supports an evidence-based non-statin option when LDL cholesterol remains above target despite maximally tolerated therapy. Patient assessment should distinguish true statin-associated symptoms from nocebo effects, drug interactions or unrelated musculoskeletal conditions, because statins remain foundational therapy. When additional treatment is needed, selection should reflect absolute ASCVD risk, expected LDL reduction, cost, route of administration and patient preference.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
2 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
3 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
3 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
3 days back
